Videos / Fluticasone furoate/umeclidinium/vilanterol single inhaler triple therapy for the management of moderate to severe COPD

Product Explainer

Fluticasone furoate/umeclidinium/vilanterol single inhaler triple therapy for the management of moderate to severe COPD

Description

In this Product Explainer, Respiratory Physician Dr Martin MacDonald explains the role of single inhaler triple therapy containing fluticasone furoate/umeclidinium/vilanterol for the management of moderate to severe COPD (5 mins).

This educational activity was developed by Healthed at the request of and with funding from GSK.

PM-AU-FVU-VID-230011 Approved October 2023.

NEXT LIVE Webcast

Days

Hours

Minutes

Seconds

Prof Andrew Sindone AM

MRAs for Heart Failure Update - New Developments

Prof David Price

COPD Exacerbation – Inhaled steroids vs Pneumonia Risks – It's Not Black and White

A/Prof Ralph Audehm & Prof Simone Strasser

Abnormal LFTs – Practical Cases Expert Q&A

Angela Newbound

Practical Strategies to Increase Vaccination Rates This Flu Season

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

28 April 2026

expert

A/Prof Martin MacDonald

Respiratory Physician, Monash Medical Centre; Head of Unit, Respiratory and General Medicine, Jessie McPherson Private Hospital

Product Explainer

Fluticasone furoate/umeclidinium/vilanterol single inhaler triple therapy for the management of moderate to severe COPD